Warsh avoided committing to a particular course of action for the December meeting, saying the Fed's decisions would remain dependent on incoming data.
US Fed Verdict: FOMC said that inflation remains elevated, while job gains have kept pace with workforce. It also added that the US economic activity is expanding at a "strong" pace. The monetary...
Market experts shared buy, sell and hold recommendations for an array of stocks including GEC, Eternal, Hindustan Zinc, Jio Platforms and Varun Beverages.
Projected 2027 401(k) limits and catch-up contributions would rise under Milliman's updated forecast, and here are six of its 10 estimates to watch before the IRS announces official limits
Speaking at the NDTV Profit IGNITE 2026, Merchant said that his foray into stock market began while discussing investment opportunities with his brother-in-law, when they came across Vodafone Idea...
ACME Solar Holdings more than doubled its net profit in Q2 FY27 as revenue approached Rs 900 crore. EBITDA also climbed sharply, although the operating margin moderated slightly compared with the...
Compare six high-yield savings accounts paying 3.50% to a conditional 5.00% APY, each with its own balance, deposit and fee rules, after the Fed's September 2026 hike
Agrawal also expressed optimism about the long-term potential of India's capital markets, pointing to the possibility of a trillion-dollar initial public offering (IPO) from the country over the next...
Investor Ramesh Damani warns US midterm elections could unsettle global markets, but says an unwinding of the AI trade could redirect investor interest towards Indian equities.
The economy may be going to hell in a handcart, but at least John Healey has cut 6p from the daily supermarket bill. That will make all the difference to beleaguered households, says Alexander McKibbin.
Shares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as investors were unnerved by weaker sales of its respiratory syncytial virus (RSV) and shingles vaccines, and recently launched medications.
Britain’s second-biggest pharmaceutical company reported a 19% decline in pre-tax profit to £1.9bn in the July to September quarter and £318m of restructuring charges, with more to come. Core operating profit and core earnings per share rose 5% and 1% respectively, however, beating analysts’ expectations.
Login
